Adentri tonapofylline: Phase III amend

Biogen Idec disclosed as part of its earnings that it plans to modify the ongoing Phase III TRIDENT-1 trial of IV Adentri tonapofylline in order to reduce the size and re-classify it as a Phase II tri...